secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001193125-22-296577
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences stockholders approve share issuance for AavantiBio merger and amended equity plan
--------------------------------------------------------------------------------

- Stockholders approved issuance of shares for the acquisition of AavantiBio under the Merger Agreement (4,054,470 for, 41,480 against).
- Approved amended 2020 Equity Incentive Plan, increasing share reserve by 866,666 to 1,533,333 shares plus annual evergreen 5% of outstanding shares.
- Equity plan proposal passed with 3,480,064 for and 614,534 against.
- Annual increase feature begins fiscal year 2023 up to fiscal 2032 at Board discretion.
- Approval removes key condition for closing the AavantiBio acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/0001193125-22-296577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/d430820d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-296577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer